Molecular Formula	C31H33F3N2O5S
Molecular Weight	602.7
Structure
State	solid
Protein binding	Extensive (> 99.9%), to both human serum albumin and α-1-acid glycoprotein.
Half life	5-6 hours
Absorption	Absorption is limited, although no absolute quantification of absorption is available.

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
MEMBRANE POTENTIAL	26.60±4.94		human	qHTS-HepG2	MMP assay	decrease	IC50	163
MEMBRANE POTENTIAL	17.34		human	HepG2	MMP assay	decrease	IC50	163
MEMBRANE POTENTIAL	29.15±2.37		rat	hepatocytes	MMP assay	decrease	IC50	163

Pictogram	Signal	Statements	Precautionary Statement Codes
		The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. H411 (100%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]	P273, P391, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Acquired immunodeficiency syndrome

Autoimmune disorder

Drug interaction

Abdominal pain (0.034)

Weight decreased (0.022)

Alanine aminotransferase increased

Amylase increased

Anaemia

Aspartate aminotransferase increased

Body temperature increased

Dermatitis

Diarrhoea

Nausea

Rash

Vomiting

White blood cell count decreased

174484-41-4	1d4y	2-Pyridinesulfonamide, N-(3-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-
2-Pyridinesulfonamide, N-(3-(1-(5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-, (R-(R*,R*))-	2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-	2o4l
2o4n	2o4p	3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide
A811642	AKOS030254403	Aptivus
Aptivus (TN)	Aptivus(TM)	C31H33F3N2O5S
CAS-174484-41-4	CHEBI:63628	CHEMBL183041
CHEMBL222559	CS-1210	CTK8E7540
D08605	DB00932	DSSTox_CID_28548
DSSTox_GSID_48622	DSSTox_RID_82820	DTXSID6048622
FT-0675248	HSDB 8083	HY-15148
J-010991	N-(3-((R)-1-((R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3,4-dihydro-2H-pyran-5-yl)propyl)phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide	N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide	N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	N-[3-[(1R)-1-[(2R)-6-oxidanyl-4-oxidanylidene-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
NCGC00182028-01	NCGC00379087-01	PNU 140690
PNU-140690	Q423404	RT-016034
SCHEMBL40629	SCHEMBL40630	TPV
Tipranavir	Tipranavir (INN)	Tipranavir [INN:BAN]
Tox21_112962	U 140690	U-140690
UNII-ZZT404XD09	W-5247	X2005
ZINC100016058	ZINC100022637	ZZT404XD09

DrugBank Name	Tipranavir
DrugBank	DB00932
CAS Number	174484-41-4, 174590-27-3, 191150-83-1
PubChem Compound	54682461
KEGG Drug	D08605
PubChem.Substance	46506257
ChEBI	63628
PharmGKB	PA163522473
ChemSpider	10482313
BindingDB	558.0
TTD	DAP001085
Wikipedia	Tipranavir
HET	TPV
DPD	12684